Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119610 · ClinicalTrials.gov registry record · Phase 1
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
A Phase 1 study of Obesity and Aging, sponsored by Sara Espinoza.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT03119610: Completed Phase 1 study of Obesity and Aging, sponsored by Sara Espinoza.
NCT03119610 is a Phase 1 study of Obesity and Aging that has completed, run by Sara Espinoza. The registered enrollment target is 23 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03119610, a Phase 1 study of Obesity and Aging, has completed, sponsored by Sara Espinoza.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
Obesity is highly prevalent in older adults and is a major cause of sarcopenia and disability in older adults. Although exercise can counteract the effects of obesity and sarcopenia, many have difficulty adhering to an exercise program and the benefits of exercise are variable. Therefore, there is an urgent need to test novel pharmacologic interventions to prevent disability and loss of independence. Oxytocin is a pituitary hormone released during parturition and lactation that is also known to suppress appetite in rodents and humans; and, recent small studies have found that intranasal oxytocin reduces body weight in adults. We propose a pilot study of intranasal oxytocin as a novel approach to promote weight loss and increase muscle mass in older subjects with sarcopenic obesity.
Primary Outcome
Intranasal oxytocin will promote weight loss and preserve muscle mass
Conditions Studied
Interventions
- DRUG Oxytocin nasal spray
- DRUG Placebo nasal spray
Study Locations (1)
Texas
- Texas Diabetic Institute - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-09-22 |
| Est. Completion | 2019-12-17 |
| Phase | Phase 1 |
What the finished NCT03119610 record still lists
NCT03119610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Oxytocin nasal spray is the first listed.
NCT03119610 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03119610 about?
NCT03119610 is a clinical study titled "The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity". Obesity is highly prevalent in older adults and is a major cause of sarcopenia and disability in older adults. Although exercise can counteract the effects of obesity and sarcopenia, many have difficulty adhering to an exercise program and the benefits of exercise are variable. Therefore, there is a...
What is the current status of trial NCT03119610?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2017-09-22. Estimated completion is 2019-12-17.
What conditions does trial NCT03119610 study?
This clinical trial studies the following conditions: Obesity, Aging, Sarcopenia, Sedentary Lifestyle, Sarcopenic Obesity.
What interventions are being tested in trial NCT03119610?
The interventions under investigation include: Oxytocin nasal spray (DRUG), Placebo nasal spray (DRUG).
Who is sponsoring clinical trial NCT03119610?
This trial is sponsored by Sara Espinoza, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03119610 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03119610's enrollment target sits among peer trials
23 928th of 1053 higher than 120 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI